Skip to main content

Advertisement

SpringerLink
Log in

Association of biomarkers of inflammation, cartilage and bone turnover with gender, disease activity, radiological damage and sacroiliitis by magnetic resonance imaging in patients with early spondyloarthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

To assess the association between biomarkers of inflammation, cartilage and bone turnover with gender, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Spondylitis Disease Activity Score (ASDAS) and bone marrow oedema in resonance magnetic imaging (MRI) of sacroiliac joints (SIJs) and radiological damage in early spondyloarthritis (SpA). Cross-sectional study of 60 patients (56.7 % females; mean age, 32.4 years) with early SpA. Sociodemographic data, clinical features, serum matrix metalloproteinase 3 (MMP-3), high sensitivity C-reactive protein (hsCRP), C-terminal cross-linking telopeptides of type I collagen (CTX-I) and urinary deoxypyridinoline, ASDAS, BASDAI, BASFI, BASRI and MRI of the SIJs were collected. The mean (SD) disease duration was 12.4 (6.8 months). Twenty-two (68.7 %) of the 32 patients had active sacroiliitis by MRI. MMP-3 and CTX I correlated with swollen joint (r = 0.515, r = 0.386, p = 0.01). hsCRP correlated with ESR (r = 0.303, p = 0.05), with CRP (r = 0.455, p = 0.01) and with total BASRI (r = 0.95, p = 0.05). Biomarkers were unrelated with the rest of variables. Levels of MMP-3 (44.3 ± 52.4 vs 24.7 ± 33.4, p < 0.05) and CTX-I (0.53 ± 0.45 vs 0.24 ± 0.38; p < 0.05) were higher in men. Our study shows that CTX-I and MMP-3 are a marker of peripheral disease activity in early SpA. Male gender had higher levels of CTX-I and MMP-3, which may indicate higher disease activity. Higher hsCRP levels trended towards correlation with more baseline radiographic damage. Therefore, these biomarkers may help identify a subgroup of patients who will need closer monitoring and more intensive treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maksymowych WP (2010) Biomarkers in spondyloarthritis. Curr Rheumatol Rep 12:318–324

    Article  CAS  PubMed  Google Scholar 

  2. De Vlam K (2010) Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol 24:671–682

    Article  PubMed  Google Scholar 

  3. Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J (2010) Comparison of a high sensitivity and standard C-reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis 69:1338–1341

    Article  CAS  PubMed  Google Scholar 

  4. Murphy G, Knäuper V, Atkinson S et al (2002) Matrix metalloproteinases in arthritic disease. Arthritis Res 4(Suppl 3):S39–S49

    Article  PubMed Central  PubMed  Google Scholar 

  5. Chen CH, Lin KC, Yu DT et al (2006) Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 45:414–420

    Article  CAS  Google Scholar 

  6. Maksymowych WP, Landewé R, Conner-Spady B et al (2007) Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56:1846–1853

    Article  CAS  PubMed  Google Scholar 

  7. Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D (1999) Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. Rheumatology (Oxford) 38:21–27

    Article  CAS  Google Scholar 

  8. Park MC, Chung SJ, Park YB, Lee SK (2008) Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis. Yonsei Med J 30:288–294

    Article  Google Scholar 

  9. Pedersen SJ, Sørensen IJ, Garnero P et al (2011) ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 70:1375–1381

    Article  CAS  PubMed  Google Scholar 

  10. Pedersen SJ, Sørensen IJ, Lambert RG et al (2011) Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondyloarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover. Arthritis Rheum 63:3789–3800

    Article  PubMed  Google Scholar 

  11. Fernández Carballido C (2010) Diagnosing early spondyloarthritis in Spain: the ESPERANZA program. [Article in Spanish]. Reumatol Clin 6:6–10

    Article  PubMed  Google Scholar 

  12. Muñoz-Fernández S, Carmona L, Collantes E et al (2011) A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program. Ann Rheum Dis 70:827–830

    Article  PubMed  Google Scholar 

  13. Rudwaleit M, Van Der Heijde D, Landewé R et al (2009) The development of Assessment of Spondyloarthritis International Society Classification Criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777–783

    Article  CAS  PubMed  Google Scholar 

  14. Rudwaleit M, Van Der Heijde D, Landewé R et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31

    Article  CAS  PubMed  Google Scholar 

  15. Dougados M, Van Der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227

    Article  CAS  PubMed  Google Scholar 

  16. Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M (1999) Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 39:878–882

    Article  Google Scholar 

  17. Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 68:18–24

    Article  CAS  PubMed  Google Scholar 

  18. Van Der Heijde D, Lie E, Kvien TK et al (2009) ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 68:1811–1818

    Article  PubMed  Google Scholar 

  19. Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285

    CAS  PubMed  Google Scholar 

  20. Mackay K, Mack C, Brophy S, Calin A (1998) The Bath Ankylosing Spondylitis Radiology Index (BASRI). A new validated approach to diseases assessment. Arthritis Rheum 41:2263–2270

    Article  CAS  PubMed  Google Scholar 

  21. Rudwaleit M, Jurik AG, Hermann KG et al (2009) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 68:1520–1527

    Article  CAS  PubMed  Google Scholar 

  22. Vandooren B, Kruithof E, Yu DT et al (2004) Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and downregulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50:2942–2953

    Article  CAS  PubMed  Google Scholar 

  23. Arends S, Van Der Veer E, Groen H et al (2011) Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol 38:1644–1650

    Article  CAS  PubMed  Google Scholar 

  24. Yang C, Gu J, Rihl M et al (2004) Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 51:691–699

    Article  CAS  PubMed  Google Scholar 

  25. Arends S, Spoorenberg A, Houtman PM et al (2012) The effect of 3 years of TNF alpha blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 14:R98. doi:10.1186/ar3823

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5:507–511

    CAS  PubMed  Google Scholar 

  27. Macdonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD (1997) Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 36:50–53

    Article  CAS  PubMed  Google Scholar 

  28. Ribbens C, Porras M, Franchimont N et al (2002) Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61:161–166

    Article  CAS  PubMed  Google Scholar 

  29. Yamanaka H, Matsuda Y, Tanaka M et al (2000) Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the 6 months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 43:852–858

    Article  CAS  PubMed  Google Scholar 

  30. Visvanathan S, Wagner C, Marini JC et al (2008) Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 67:511–517

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Maksymowych WP, Rahman P, Shojania K et al (2008) Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis. J Rheumatol 35:2030–2037

    CAS  PubMed  Google Scholar 

Download references

Disclosures

None.

Source of support

The ESPERANZA programme has been supported by an unrestricted graft from Pfizer.

Author information

Authors and Affiliations

  1. Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Avda. Budapest s/n, 28922, Alcorcón, Madrid, Spain

    Raquel Almodóvar & Pedro Zarco-Montejo

  2. Rheumatology Department, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

    Valeria Ríos & Xavier Juanola

  3. Service of Clinical Laboratory, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain

    Sara Ocaña & María-Luisa Casas

  4. Research Unit, Sociedad Española de Reumatología (SER), Madrid, Spain

    Milena Gobbo

Authors
  1. Raquel Almodóvar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Valeria Ríos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara Ocaña
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Milena Gobbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. María-Luisa Casas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pedro Zarco-Montejo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xavier Juanola
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raquel Almodóvar.

Additional information

Milena Gobbo, Raquel Almodóvar, Pedro Zarco-Montejo, and Xavier Juanola are members of Grupo Español para el Estudio de las Espondiloartritis de la Sociedad Española Reumatología (GRESSER).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Almodóvar, R., Ríos, V., Ocaña, S. et al. Association of biomarkers of inflammation, cartilage and bone turnover with gender, disease activity, radiological damage and sacroiliitis by magnetic resonance imaging in patients with early spondyloarthritis. Clin Rheumatol 33, 237–241 (2014). https://doi.org/10.1007/s10067-013-2349-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-013-2349-5

Keywords

Search

Navigation